ChondroGene
ChondroGene Limited is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews’ first product in development, ColonSentry(TM), is a blood-based test that can detect colon cancer and pre-cancerous polyps.
Transactions
This announcement as a matter of record only
This announcement as a matter of record only
News
TORONTO, CANADA (May 26, 2006): ChondroGene Limited (TSX Venture: CDG) is pleased to announce that it has completed the $20 million bought deal private placement financing originally announced on May...
TORONTO, CANADA (September 13, 2004): ChondroGene Limited (TSX-V: CDG) reported today that it has raised US$500,000 by way of a brokered private placement in Canada PowerOne Capital Markets Limited...
About
PowerOne is a long term investor focused on providing early stage capital and advisory services to emerging growth companies. Since inception in 2003, PowerOne has assisted private and public companies across an array of sectors globally.
PowerOne is an Exempt Market Dealer and is registered in Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, Nova Scotia and Quebec.
